Email this Page

1. OVERVIEW
2. TABLE OF CONTENTS
3. CONTACT INFO
4. TECHNICAL HELP

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

PER Editorial Staff
No relevant relationships to disclose

Satellite Faculty

Alex Adjei, MD, PhD
Research Funding – Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline

David Gandara, MD
Research Funding – Bristol-Myers Squibb Company, Eli Lilly and Company
Paid Consultant – AstraZeneca; Bayer Pharmaceuticals Corporation; Genentech, Inc.; Pfizer Inc.; sanofi-aventis U.S.

Glenwood Goss, MD
Research Funding – AstraZeneca
Paid Consultant – AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc., Roche Pharmaceuticals

Roy Herbst, MD, PhD
Research Funding – Amgen; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.
Paid Consultant – Amgen; AstraZeneca; Bristol-Myers Squibb Company; Genentech, Inc.
Speaker’s Bureau – Eli Lilly and Company

Thomas Lynch, MD
Paid Consultant – Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech, Inc.; Merck & Co., Inc.; OSI Pharmaceuticals; Roche Pharmaceuticals; sanofi-aventis U.S.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Genentech BioOncology.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users If you need to upgrade your Web browser, follow one of the links listed below:

• Microsoft Internet Explorer Downloads (Outside Source)
• Mozilla Firefox Product Page (Outside Source)

Macintosh Users Compatible Web browsers include Firefox (Outside Source) and Apple Safari (Outside Source)

Illustration

Both intrinsic changes leading to dysregulated growth and metastatic behavior in a precancerous cell and extrinsic factors in the microenvironment contribute to the development of tumors. Interactions between tumor cells and the extracellular matrix, as well as with other cell types, can influence the behavior of tumor cells. Consequently, these cell-matrix and cell-cell interactions provide additional potential targets for cancer therapy. Intratumoral angiogenesis is key to continued malignant growth, and the targeting of this process with antibodies to vascular endothelial growth factor was among the first proofs of concept of this approach. Additional targets in the tumor microenvironment include fibroblasts, which can influence the behavior of precancerous cells, and inflammatory cells, which generate cytokines and proteases that further stimulate tumor cells.

Disclaimer

The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949–0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Refining and Personalizing Treatment for Non–Small-Cell Lung Cancer
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367–3456
Fax: (214) 367–3304
E–mail: editor@pergrouplp.com

About the Illustration About the Illustration:

Both intrinsic changes leading to dysregulated growth and metastatic behavior in a precancerous cell and extrinsic factors in the microenvironment contribute to the development of tumors. Interactions between tumor cells and the extracellular matrix, as well as with other cell types, can influence the behavior of tumor cells. Consequently, these cell-matrix and cell-cell interactions provide additional potential targets for cancer therapy. Intratumoral angiogenesis is key to continued malignant growth, and the targeting of this process with antibodies to vascular endothelial growth factor was among the first proofs of concept of this approach. Additional targets in the tumor microenvironment include fibroblasts, which can influence the behavior of precancerous cells, and inflammatory cells, which generate cytokines and proteases that further stimulate tumor cells.

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:

1. Genentech BioOncology